Skip to main content
SpringerLink
Log in

Clinical and histological prognostic factors in axillary node-negative breast cancer: Univariate and multivariate analysis with relation to 5 year recurrence

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

In the recent years several studies have shown that about 30% of cases with axillary node-nagative breast cancer suffer relapse of the disease. Our attempt was made to evaluate the most significant prognostic factors to predict this high risk group which may be benefited from adjuvant treatment. For this purpose, we selected 9 patients out of 80 cases of node-negative breast cancer who had been followed up at least for 5 years and had the recurrence of the disease. For comparison, 16 patients from the same group who did not have relapse were selected on a random basis. Histology, receptor status, AgNOR, DNA flow cytometry and various immunohistochemical parameters were compared between the groups with recurrence and that without recurrence.

On univariate analysis, tumor size, immunohistochemical expressions of PCNA, MIB-1, c-erbB-2 and S-phase fraction were significantly different between the above two groups. By multivariate analysis, immunohistochemicalc-erbB-2 expression (more than 50% of cancer cells) was an independent parameter.

As a summary from our studies, c-erbB-2 immunohistochemical staining on paraffin sections might be the best independent prognostic factor in axillary node-negative breast cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ABC:

Avidin biotin peroxidase complex

AgNOR:

Arygrophilic nucleolar organizer

DCC:

Dexrran coated charcoal

ER:

Estrogen reseptot

NOR’s:

Nucleolar organizer regions

PCNA:

Proliferating cell unclear antigen

References

  1. Fisher B, Redmond R, Fisher ER,et al. Relative worth of oestrogen and progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients; Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.J Clin Oncol 6:1076–1087, 1988.

    PubMed  CAS  Google Scholar 

  2. Sigurdsson H, Baldetorp B, Borg A,et al: Indicators of prognosis in node negative breast cancer.N Engl J Med 322:1045–1053, 1990.

    PubMed  CAS  Google Scholar 

  3. Fisher B, Redmond C, Dimitrov NV,et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node negative breast cancer who have estrogen receptor negative tumors.N Engl J Med 320:473–478, 1989.

    PubMed  CAS  Google Scholar 

  4. Fisher B, Costantino J, Redmond C,et al: A randomized clinical trial evaluating tamoxiphen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumors.N Engl J Med 320:479–484, 1989.

    PubMed  CAS  Google Scholar 

  5. Mansour EG, Gray R, Shatila AH,et al: Efficacy of adjuvant chemotherapy in high risk node negative breast cancer.N Engl J Med 320:485–490, 1989.

    PubMed  CAS  Google Scholar 

  6. Baum MB, Brinkley DM, Dosset JA,et al: Controlled trial of tamoxiphen as a single adjuvant agent in the management of early breast cancer: Analysis at eight years by Nolvadex Adjuvant Trial Organisation.Br J Cancer 57:608–611, 1988.

    Google Scholar 

  7. De Vita VT Jr: Breast cancer therapy; Exercising all our options.N Engl J Med 320:527–529, 1989.

    PubMed  Google Scholar 

  8. Peters LJ, Hopwood JE, Withers HR,et al: Predictive assays of tumor radiocurability.Can Treat Sym 1:67- 74, 1984.

    Google Scholar 

  9. Wong WW, Vijayakumar S, Weichselbaum RR: Prognostic indicators in node negative early stage breast cancer.Am J Med 92:539–548, 1992.

    Article  PubMed  CAS  Google Scholar 

  10. Haybittle JL, Blarney RW, Elston CW,et al. A prognostic index in primary breast cancer.Br J Cancer 45:361–366, 1982.

    PubMed  CAS  Google Scholar 

  11. McGuire WL, Tandon AK, Allred DC,et al: Prognosis and treatment decisions in patiemts with breast cancer without axillary node involvement.Cancer 70: 1775–1781, 1992.

    Article  PubMed  CAS  Google Scholar 

  12. Johnson H, Masood S, Belluco C,et al: Prognostic factors in node negative breast cancer.Arch Surg 127: 1386–1391, 1992.

    PubMed  Google Scholar 

  13. Bacus SS, Ruby SG: Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma.Pathol Annu 28 (part I):179–204, 1993.

    PubMed  Google Scholar 

  14. Ellias JM, Qiao L, Heimann A,et al: Paraffin embedded breast carcinomas for the immunohistochemical study of prognostic factors.J Histotechnol 15:315–320, 1992.

    Google Scholar 

  15. O’Reilly SM, Richards MA: Is DNA flow cytometry a useful investigation in breast cancer?Eur J Cancer 28:504–507, 1992.

    Article  PubMed  CAS  Google Scholar 

  16. Callahan R: p53 mutation, another cancer prognostic factor.JNCI 84:826–827, 1992.

    Article  PubMed  CAS  Google Scholar 

  17. Egan MJ, Crocker J: Nucleolar organiser regions in pathology.Br J Cancer 65:1–7, 1992.

    PubMed  CAS  Google Scholar 

  18. Rochefort H: Biological and clinical significance of cathepsin D in breast cancer.Acta Oncol 31:125–130, 1992.

    Article  PubMed  CAS  Google Scholar 

  19. Perren TJ:c-erbB-2 oncogene as a prognostic marker in breast cancer.Br J Cancer 63:328–332, 1991.

    PubMed  CAS  Google Scholar 

  20. Brown DC, Gatter KC: Monoclonal antibody Ki-67; Its use in histopathology.Histopathology 17:489–503, 1990.

    Article  PubMed  CAS  Google Scholar 

  21. Yu CCW, Woods AL, Levinson DA: The assessment of cellular proliferation by immunohistochemistry; A review of currently available methods and their applications.Histochem J 24:121–131, 1992.

    Article  PubMed  CAS  Google Scholar 

  22. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer; 1, The value of histological grade in breast cancer; Experience from a long-term followup.Histopathology 19:403–410, 1991.

    Article  PubMed  CAS  Google Scholar 

  23. Chiu KY, Loke SL, Wong KK: Improved silver technique for showing nucleolar organizer regions in paraffin wax sections.J Clin Pathol 42:992–994, 1989.

    Article  PubMed  CAS  Google Scholar 

  24. Key G, Becker MHG, Duchrow M,et al: New Ki-67 equivalent murine monoclonal antibodies (MIB 1–3) prepared against recombinant parts of the Ki-67 antigen (Abstract 186).Ann Cell Pathol 4:181, 1992.

    Google Scholar 

  25. Hall PA, Levinson DA, Woods AL,et al: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections; An index of cell proliferation with evidance of deregulated expression in some neoplasms.J Pathol 162:285–294, 1990.

    Article  PubMed  CAS  Google Scholar 

  26. Banks L, Matiashenski C, Crawford L: Isolation of human p53 specific monoclonal antibodies and their use in human p53 expression.Eur J Biochem 155:529 -534, 1986.

    Article  Google Scholar 

  27. Gullick WJ, Borger MS, Bennett PLP,et at. Expression of the c-erbB-2 protein in normal and transformed cells.Int J Cancer 40:246–254, 1987.

    Article  PubMed  CAS  Google Scholar 

  28. Henry JA, McCarthy AL, Angus B,et al: Prognostic significance of the estrogen regulated protein, cathepsin D in breast cancer.Cancer 65:265–271, 1990.

    Article  PubMed  CAS  Google Scholar 

  29. Hedley DW, Friedlander ML, Taylor IW,et al: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.J Histochem Cytochem 31:1333–1335, 1983.

    PubMed  CAS  Google Scholar 

  30. McGuire WL: Adjuvant therapy of node negative breast cancer.N Engl J Med 320:525–527, 1989.

    PubMed  CAS  Google Scholar 

  31. Kerns B-JM, Jordan PA, Huper G,et al: Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.Modern Pathol 6: 673–678, 1993.

    CAS  Google Scholar 

  32. Isola JJ, Holli K, Oksa H,et al: Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.Cancer 73:652–658, 1994.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Tokai Universiry School of Medicine, Bohseidai, 259-11, Isehara, Japan

    Ajay kumar Khanna, Yutaka Tokuda, Makiko Tanaka, Tomoo Tajima & Toshio Mitomi

  2. Department of Pathology, Tokai University School of Medicine, Bohseidai, 259-11, Isehara, Japan

    Makoto Shibuya & R Yoshiyuki Osamura

  3. Division of Electron Microscopy, Tokai University School of Medicine, Bohseidai, 259-11, Isehara, Japan

    Tadashi Sekine

  4. Departmenr of Surgery, Institute of Medical Sciences, Banaras Hindu University, 221 005, Varanasi, India

    Ajay kumar Khanna

Authors
  1. Ajay kumar Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaka Tokuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Shibuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makiko Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tadashi Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoo Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Yoshiyuki Osamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshio Mitomi
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Khanna, A.k., Tokuda, Y., Shibuya, M. et al. Clinical and histological prognostic factors in axillary node-negative breast cancer: Univariate and multivariate analysis with relation to 5 year recurrence. Breast Cancer 2, 51–58 (1995). https://doi.org/10.1007/BF02966896

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966896

Key words

Search

Navigation